Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting - Seite 3

About Tuberous Sclerosis Complex (TSC)
Tuberous sclerosis complex (TSC) is a rare genetic condition that affects approximately 50,000 individuals in the U.S. and nearly one million people worldwide.⁵ At least two children born each day will develop TSC, with an estimated prevalence of one in 6,000 newborns.⁵ The condition causes mostly benign tumors to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs ⁶ and is a leading cause of genetic epilepsy.⁷ TSC often occurs in the first year of life as either focal seizures or infantile spasms¹ and is associated with an increased risk of autism and intellectual disability.⁸ The severity of the condition can vary widely. In some children the disease is very mild, while others may experience life-threatening complications.⁶

Epilepsy is present in about 85% of patients with TSC and may progress to become intractable to medication.^1,2,3 More than 60% of individuals with TSC do not achieve seizure control⁴ with standard treatments such as antiepileptic drugs, epilepsy surgery, ketogenic diet, or vagus nerve stimulation² compared to 30-40% of individuals with epilepsy who do not have TSC who are drug resistant.^9,10

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW’s lead product, EPIDIOLEX (cannabidiol) oral solution is commercialized in the US by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. This product has received approval in Europe under the tradename EPIDYOLEX. The Company continues to evaluate EPIDIOLEX in additional rare conditions including tuberous sclerosis complex (TSC) and Rett syndrome. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the Company is now advancing a late stage program in order to seek FDA approval. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, autism, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com.